A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights

1. Chu K, Dupuy D. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 2014; 14: 199–208. doi: 10.1038/nrc3672 ChuK DupuyD Thermal ablation of tumours: biological mechanisms and advances in therapy Nat Rev Cancer 2014 14 199 208 10.1038/nrc3672 Open DOISearch in Google Scholar

2. Li Y, Wang N, Fan LF, Zhao PF, Li JH, Huang L, et al. Robust electrical impedance tomography for biological application: a mini review. Heliyon 2023; 9: e151195. doi: 10.1016/j.heliyon.2023.e15195 LiY WangN FanLF ZhaoPF LiJH HuangL Robust electrical impedance tomography for biological application: a mini review Heliyon 2023 9 e151195 10.1016/j.heliyon.2023.e15195 Open DOISearch in Google Scholar

3. Zhu FY, Liu W, Li P, Zhao H, Deng X, Wang HL. Electric/magnetic intervention for bone regeneration: a systematic review and network meta-analysis. Tisuue Eng Part B Rev 2023; 29: 217–31. doi: 10.1089/ten.teb.2022.0127 ZhuFY LiuW LiP ZhaoH DengX WangHL Electric/magnetic intervention for bone regeneration: a systematic review and network meta-analysis Tisuue Eng Part B Rev 2023 29 217 31 10.1089/ten.teb.2022.0127 Open DOISearch in Google Scholar

4. Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman, et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res 2004; 64: 3288–95. doi: 10.1158/0008-5472.CAN-04-0083 KirsonED GurvichZ SchneidermanR DekelE ItzhakiA Wasserman Disruption of cancer cell replication by alternating electric fields Cancer Res 2004 64 3288 95 10.1158/0008-5472.CAN-04-0083 Open DOISearch in Google Scholar

5. Kirson ED, Dbalý V, Tovarys F, Vymazal J, Soustiel JF, Itzhakin F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A 2007; 104: 10152–7. doi: 10.1073/pnas.0702916104 KirsonED DbalýV TovarysF VymazalJ SoustielJF ItzhakinF Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors Proc Natl Acad Sci U S A 2007 104 10152 7 10.1073/pnas.0702916104 Open DOISearch in Google Scholar

6. Kirson ED, Dbalý V, Rochlitz C, Tovaryš F, Salzberg M, Palti Y. Treatment of locally advanced solid tumors using alternating electric fields (TTFields) - a translational study. [abstract]. Proceedings: AACR Annual Meeting 2023; April 14–19, 2023; Orlando, FL; Part 1. Cancer Res 2006; 66(8 Suppl): 1233. KirsonED DbalýV RochlitzC TovaryšF SalzbergM PaltiY Treatment of locally advanced solid tumors using alternating electric fields (TTFields) - a translational study. [abstract]. Proceedings: AACR Annual Meeting 2023; April 14–19, 2023; Orlando, FL; Part 1 Cancer Res 2006 66 8 Suppl 1233 Search in Google Scholar

7. Mun EJ, Babiker HM, Weinberg U, Kirson ED, Von Hoff DD. Tumor-treating fields: a fourth modality in cancer treatment. Clin Cancer Res, 2018; 24: 266–75. doi: 10.1158/1078-0432.CCR-17-1117 MunEJ BabikerHM WeinbergU KirsonED Von HoffDD Tumor-treating fields: a fourth modality in cancer treatment Clin Cancer Res 2018 24 266 75 10.1158/1078-0432.CCR-17-1117 Open DOISearch in Google Scholar

8. Kirson ED, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman RS, et al. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis 2009; 26: 633–40. doi: 10.1007/s10585-009-9262-y KirsonED GiladiM GurvichZ ItzhakiA MordechovichD SchneidermanRS Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs Clin Exp Metastasis 2009 26 633 40 10.1007/s10585-009-9262-y Open DOISearch in Google Scholar

9. Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Ann N Y Acad Sci 2013; 1291: 86–95. doi: 10.1111/nyas.12112 DaviesAM WeinbergU PaltiY Tumor treating fields: a new frontier in cancer therapy Ann N Y Acad Sci 2013 1291 86 95 10.1111/nyas.12112 Open DOISearch in Google Scholar

10. Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 2012; 48: 2192–202. doi: 10.1016/j.ejca.2012.04.011 StuppR WongET KannerAA SteinbergD EngelhardH HeideckeV NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality Eur J Cancer 2012 48 2192 202 10.1016/j.ejca.2012.04.011 Open DOISearch in Google Scholar

11. Hottinger AF, Pacheco P, Stupp R. Tumor treating fields: a novel treatment modality and its use in brain tumors. Neuro Oncol 2016; 18: 1338–49. doi: 10.1093/neuonc/now182 HottingerAF PachecoP StuppR Tumor treating fields: a novel treatment modality and its use in brain tumors Neuro Oncol 2016 18 1338 49 10.1093/neuonc/now182 Open DOISearch in Google Scholar

12. Leal T, Bueno R, Havel L, Ward J. Tumor treating fields (150 kHz) concurrent with immune check point inhibitors for stage 4 non-small cell lung cancer (NSCLC) in phase 3 LUNAR study. [abstract]. J Thorac Oncol 2021; 16: S651. P82.01. doi: 10.1016/j.jtho.2021.01.1192 LealT BuenoR HavelL WardJ Tumor treating fields (150 kHz) concurrent with immune check point inhibitors for stage 4 non-small cell lung cancer (NSCLC) in phase 3 LUNAR study. [abstract] J Thorac Oncol 2021 16 S651 P82.01. 10.1016/j.jtho.2021.01.1192 Open DOISearch in Google Scholar

13. Weinberg U, Farber O, Giladi M, Bomzon Z, Kirson ED. Tumor treating field concurrent with standard of care for stage 4 non-small cell lung cancer (NSCLC) following platinum failure: Phase III LUNAR study. [abstract]. ESMO, October 2018. Ann Oncol 2018, 29: viii543. doi: 10.1093/annonc/mdy292.120 WeinbergU FarberO GiladiM BomzonZ KirsonED Tumor treating field concurrent with standard of care for stage 4 non-small cell lung cancer (NSCLC) following platinum failure: Phase III LUNAR study. [abstract]. ESMO, October 2018 Ann Oncol 2018 29 viii543 10.1093/annonc/mdy292.120 Open DOISearch in Google Scholar

14. Weinberg U, Farber O, Giladi M, Bomzon Z, Kirson ED. TTFields combined with PD-1 inhibitors or docetaxel for 2nd line treatment of non-small cell lung cancer (NSCLC): Phase 3 LUNAR study. [abstract]. ESMO, April 2017. Ann Oncol 2017; 28: ii51. doi: 10.1093/annonc/mdx091.065 WeinbergU FarberO GiladiM BomzonZ KirsonED TTFields combined with PD-1 inhibitors or docetaxel for 2nd line treatment of non-small cell lung cancer (NSCLC): Phase 3 LUNAR study. [abstract]. ESMO, April 2017 Ann Oncol 2017 28 ii51 10.1093/annonc/mdx091.065 Open DOISearch in Google Scholar

15. Pless M, Droege C, von Moos R, Salzberg M, Betticher D. A Phase I/II trial of tumor treating fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. Lung Cancer 2013; 81: 445–50. doi: 10.1016/j.lungcan.2013.06.025 PlessM DroegeC von MoosR SalzbergM BetticherD A Phase I/II trial of tumor treating fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer Lung Cancer 2013 81 445 50 10.1016/j.lungcan.2013.06.025 Open DOISearch in Google Scholar

16. Vergote I, VonMoos R, Manso L, Van Nieuwenhuysen E, Concin N, Sessa C. Tumor treating fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study. Gynecol Oncol 2018; 150: 471–7. doi: 10.1016/j.ygyno.2018.07.018 VergoteI VonMoosR MansoL Van NieuwenhuysenE ConcinN SessaC Tumor treating fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study Gynecol Oncol 2018 150 471 7 10.1016/j.ygyno.2018.07.018 Open DOISearch in Google Scholar

17. Picozzi V, Macarulla T, Becerra C, Dragovich T. Front-line treatment of locally advanced pancreatic adenocarcinoma with tumour treating fields concomitant with gemcitabine and nab-paclitaxel: the phase 3 PANOVA-3 study. [abstract]. ESMO, Jun 2022. P-120. Ann Oncol 2022; 33: S292. doi: 10.1016/j.annonc.2022.04.210 PicozziV MacarullaT BecerraC DragovichT Front-line treatment of locally advanced pancreatic adenocarcinoma with tumour treating fields concomitant with gemcitabine and nab-paclitaxel: the phase 3 PANOVA-3 study. [abstract]. ESMO, Jun 2022. P-120 Ann Oncol 2022 33 S292 10.1016/j.annonc.2022.04.210 Open DOISearch in Google Scholar

18. Rivera F, Benavides M, Gallego J, Guillen-Ponce C, Lopz-Martin J, Kung M. Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: results of the PANOVA phase 2 study. Pancreatology 2019; 19: 64–72. doi: 10.1016/j.pan.2018.10.004 RiveraF BenavidesM GallegoJ Guillen-PonceC Lopz-MartinJ KungM Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: results of the PANOVA phase 2 study Pancreatology 2019 19 64 72 10.1016/j.pan.2018.10.004 Open DOISearch in Google Scholar

19. Giladi M, Schneiderman RS, Porat Y, Munster M, Itzhaki A, Mordechovich D, et al. Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields. Pancreatology 2014; 14: 54–63. doi: 10.1016/j.pan.2013.11.009 GiladiM SchneidermanRS PoratY MunsterM ItzhakiA MordechovichD Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields Pancreatology 2014 14 54 63 10.1016/j.pan.2013.11.009 Open DOISearch in Google Scholar

20. Leonard F, Kelly J. Clinical value of TTFields treatment in mesothelioma using ASCO and ESMO frameworks. Int J Radiat Oncol Biol Phys 2019; 105: E545–6. doi: 10.1016/j.ijrobp.2019.06.1271 LeonardF KellyJ Clinical value of TTFields treatment in mesothelioma using ASCO and ESMO frameworks Int J Radiat Oncol Biol Phys 2019 105 E545 6 10.1016/j.ijrobp.2019.06.1271 Open DOISearch in Google Scholar

21. Mumblat H, Martinez-Conde A, Braten O, Munster M, Dor-On E, Schneiderman RS, et al. Tumor treating fields (TTFields) downregulate the Fanconi anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical model. Lung Cancer 2021; 160: 99–110. doi: 10.1016/j.lungcan.2021.08.011. MumblatH Martinez-CondeA BratenO MunsterM Dor-OnE SchneidermanRS Tumor treating fields (TTFields) downregulate the Fanconi anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical model Lung Cancer 2021 160 99 110 10.1016/j.lungcan.2021.08.011 Open DOISearch in Google Scholar

22. Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, et al. Tumour treating fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncol 2019; 20: 1702–9. doi: /10.1016/S1470-2045(19)30532-7. CeresoliGL AertsJG DziadziuszkoR RamlauR CedresS van MeerbeeckJP Tumour treating fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial Lancet Oncol 2019 20 1702 9 10.1016/S1470-2045(19)30532-7 Open DOISearch in Google Scholar

23. Grosu A, Touchefeu Y, Brunner T, Gkika E, Thimme R, Cubillo A. Phase 2 HEPANOVA study of tumor treating fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma (HCC): interim safety analysis. [abstract]. P-215. ESMO, Jul 2020. Ann Oncol 2020; 31: S160. doi: 10.1016/j.annonc.2020.04.297 GrosuA TouchefeuY BrunnerT GkikaE ThimmeR CubilloA Phase 2 HEPANOVA study of tumor treating fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma (HCC): interim safety analysis. [abstract]. P-215. ESMO, Jul 2020 Ann Oncol 2020 31 S160 10.1016/j.annonc.2020.04.297 Open DOISearch in Google Scholar

24. Gera N, Yang A, Holtzman TS, Lee SX, Wong ET, Swanson KD. Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit. PLoS One 2015; 10: 0125269. doi: 10.1371/journal.pone.0125269 GeraN YangA HoltzmanTS LeeSX WongET SwansonKD Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit PLoS One 2015 10 0125269 10.1371/journal.pone.0125269 Open DOISearch in Google Scholar

25. Giladi M, Schneiderman R, Voloshin T, Porat Y, Munster M, Blat R, et al. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep 2015; 5: 18046. doi: 10.1038/srep18046 GiladiM SchneidermanR VoloshinT PoratY MunsterM BlatR Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells Sci Rep 2015 5 18046 10.1038/srep18046 Open DOISearch in Google Scholar

26. Wang XB, Vykoukal J, Becker FF, Gascoyne PRC. Separation of polystyrene microbeads using dielectrophoretic/gravitational field-flow-fractionation. Biophys J 1998; 74: 2689–701. doi: 10.1016/S0006-3495(98)77975-5 WangXB VykoukalJ BeckerFF GascoynePRC Separation of polystyrene microbeads using dielectrophoretic/gravitational field-flow-fractionation Biophys J 1998 74 2689 701 10.1016/S0006-3495(98)77975-5 Open DOISearch in Google Scholar

27. Pethig R. Review article – dielectrophoresis: status of the theory, technology, and applications. Biomicrofluidics 2010; 4: 022811. doi: 10.1063/1.3456626. PethigR Review article – dielectrophoresis: status of the theory, technology, and applications Biomicrofluidics 2010 4 022811 10.1063/1.3456626 Open DOISearch in Google Scholar

28. Tuszynski JA, Wenger C, Friesen DE, Preto J. An overview of sub-cellular mechanisms involved in the action of TTFields. Int J Environ Res Public Health 2016; 13: 1128. doi: 10.3390/ijerph13111128 TuszynskiJA WengerC FriesenDE PretoJ An overview of sub-cellular mechanisms involved in the action of TTFields Int J Environ Res Public Health 2016 13 1128 10.3390/ijerph13111128 Open DOISearch in Google Scholar

29. Li X, Yang F, Rubinsky B. A theoretical study on the biophysical mechanisms by which tumor treating fields affect tumor cells during mitosis. IEEE Trans Biomed Eng 2020; 67: doi: 2594–602. 10.1109/TBME.2020.2965883 LiX YangF RubinskyB A theoretical study on the biophysical mechanisms by which tumor treating fields affect tumor cells during mitosis IEEE Trans Biomed Eng 2020 67 2594 602 10.1109/TBME.2020.2965883 Open DOISearch in Google Scholar

30. Karanam NK, Ding L, Aroumougame A, Story MD. Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy. Transl Res 2020; 217: 33–46. doi: 10.1016/j.trsl.2019.10.003 KaranamNK DingL AroumougameA StoryMD Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy Transl Res 2020 217 33 46 10.1016/j.trsl.2019.10.003 Open DOISearch in Google Scholar

31. Kessler A, Frömbling GE, Gross F, Hahn M, Dzokou W, Ernestus RI, et al. Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition. Cell Death Discov 2018; 4: 77. doi: 10.1038/s41420-018-0079-9 KesslerA FrömblingGE GrossF HahnM DzokouW ErnestusRI Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition Cell Death Discov 2018 4 77 10.1038/s41420-018-0079-9 Open DOISearch in Google Scholar

32. Kirson ED, Schneiderman RS, Dbalý V, Tovarys F, Vymazal J, Itzhaki A, et al. Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys 2009; 9: 1. doi: 10.1186/1756-6649-9-1 KirsonED SchneidermanRS DbalýV TovarysF VymazalJ ItzhakiA Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields) BMC Med Phys 2009 9 1 10.1186/1756-6649-9-1 Open DOISearch in Google Scholar

33. Kirson ED, Dbalý V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci 2007; 104: 10152–7. doi: 10.1073/pnas.0702916104 KirsonED DbalýV TovarysF VymazalJ SoustielJF ItzhakiA Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors Proc Natl Acad Sci 2007 104 10152 7 10.1073/pnas.0702916104 Open DOISearch in Google Scholar

34. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clinic Oncol 1999; 17: 2572–8. doi: 10.1200/jco.1999.17.8.2572 WongET HessKR GleasonMJ JaeckleKA KyritsisAP PradosMD Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials J Clinic Oncol 1999 17 2572 8 10.1200/jco.1999.17.8.2572 Open DOISearch in Google Scholar

35. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J med 2005; 352: 987–96. doi: 10.1056/NEJMoa043330 StuppR MasonWP van den BentMJ WellerM FisherB TaphoornMJ Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J med 2005 352 987 96 10.1056/NEJMoa043330 Open DOISearch in Google Scholar

36. Benson L. Tumor treating fields technology: alternating electric field therapy for the treatment of solid tumors. Semin Oncol Nurs 2018; 34: 137–50. doi: 10.1016/j.soncn.2018.03.005 BensonL Tumor treating fields technology: alternating electric field therapy for the treatment of solid tumors Semin Oncol Nurs 2018 34 137 50 10.1016/j.soncn.2018.03.005 Open DOISearch in Google Scholar

37. Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 2015; 314: 2535–43. doi: 10.1001/jama.2015.16669 StuppR TaillibertS KannerAA KesariS SteinbergDM TomsSA Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial JAMA 2015 314 2535 43 10.1001/jama.2015.16669 Open DOISearch in Google Scholar

38. Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 2017; 318: 2306–16. doi: 10.1001/jama.2017.18718 StuppR TaillibertS KannerA ReadW SteinbergD LhermitteB Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial JAMA 2017 318 2306 16 10.1001/jama.2017.18718 Open DOISearch in Google Scholar

39. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol 2016; 893: 1–19. doi: 10.1007/978-3-319-24223-1_1 TorreLA SiegelRL JemalA Lung cancer statistics Adv Exp Med Biol 2016 893 1 19 10.1007/978-3-319-24223-1_1 Open DOISearch in Google Scholar

40. Grosso F Mądrzak J, Crinò L, Chella A, Weinberg U, Ceresoli GL. STELLAR – a phase II trial of TTFields with chemotherapy for first line treatment of malignant mesothelioma. J Thorac Oncol 2016; 11: S147–S50. doi: 10.1016/S1556-0864(16)30322-7 GrossoF MądrzakJ CrinòL ChellaA WeinbergU CeresoliGL STELLAR – a phase II trial of TTFields with chemotherapy for first line treatment of malignant mesothelioma J Thorac Oncol 2016 11 S147 S50 10.1016/S1556-0864(16)30322-7 Open DOISearch in Google Scholar

41. Ceresoli Gl, et al; NovoCure Ltd. Safety and efficacy of TTFields (150 kHz) concomitant with Pemetrexed and cisplatin or carboplatin in malignant pleural mesothelioma (STELLAR). ClinicalTrials.gov. Identifier (NCT number): NCT02397928. Available at: https://clinicaltrials.gov/ct2/show/NCT02397928?term=NCT+02397928&draw=2&rank=1 CeresoliGl NovoCure Ltd Safety and efficacy of TTFields (150 kHz) concomitant with Pemetrexed and cisplatin or carboplatin in malignant pleural mesothelioma (STELLAR) ClinicalTrials.gov. Identifier (NCT number): NCT02397928 Available at: https://clinicaltrials.gov/ct2/show/NCT02397928?term=NCT+02397928&draw=2&rank=1 Search in Google Scholar

42. Ceresoli G, Aerts J, Madrzak J, Dziadziuszko R, Ramlau R, Cedres S, et al. STELLAR: final results of a Phase 2 Trial of TTFields with chemotherapy for first-line treatment of malignant pleural mesothelioma. [abstract]. VIII641. ESMO, Oct 2018. J Thorac Oncol 2018; 13(Suppl 8): S397–8. doi: 10.1093/annonc/mdy301.001. CeresoliG AertsJ MadrzakJ DziadziuszkoR RamlauR CedresS STELLAR: final results of a Phase 2 Trial of TTFields with chemotherapy for first-line treatment of malignant pleural mesothelioma. [abstract]. VIII641. ESMO, Oct 2018 J Thorac Oncol 2018 13 Suppl 8 S397 8 10.1093/annonc/mdy301.001 Open DOISearch in Google Scholar

43. Pless M, et al; NovoCure Ltd. NovoTTF-100L in combination with pemetrexed (Alimta^®) for advanced non-small cell lung cancer. ClinicalTrials.gov. Identifier (NCT number): NCT00749346. Available at: https://clinicaltrials.gov/ct2/show/record/NCT00749346?term=NCT+00749346&draw=2&rank=1 PlessM NovoCure Ltd. NovoTTF-100L in combination with pemetrexed (Alimta^®) for advanced non-small cell lung cancer ClinicalTrials.gov. Identifier (NCT number): NCT00749346 Available at: https://clinicaltrials.gov/ct2/show/record/NCT00749346?term=NCT+00749346&draw=2&rank=1 Search in Google Scholar

44. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2023; 41: 2682–90. doi: 10.1200/JCO.22.02546 HannaN ShepherdFA FossellaFV PereiraJR De MarinisF von PawelJ Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 2023 41 2682 90 10.1200/JCO.22.02546 Open DOISearch in Google Scholar

45. NovoCure GmbH. Effect of tumor treating fields (TTFields) (150 kHz) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure (LUNAR). ClinicalTrials.gov. Identifier (NCT number): NCT02973789. Available at: https://clinicaltrials.gov/ct2/show/NCT02973789?term=NCT02973789&draw=2&rank=1 NovoCure GmbH Effect of tumor treating fields (TTFields) (150 kHz) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure (LUNAR) ClinicalTrials.gov. Identifier (NCT number): NCT02973789 Available at: https://clinicaltrials.gov/ct2/show/NCT02973789?term=NCT02973789&draw=2&rank=1 Search in Google Scholar

46. Voloshin T, Munster M, Blatt R, Shteingauz A, Roberts PC, Schmelz EM, et al. Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo. Int J Cancer 2016; 139: 2850–8. doi: 10.1002/ijc.30406 VoloshinT MunsterM BlattR ShteingauzA RobertsPC SchmelzEM Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo Int J Cancer 2016 139 2850 8 10.1002/ijc.30406 Open DOISearch in Google Scholar

47. Lok E, San P, White V, Liang O, Widick PC, Reddy SP, et al. Tumor treating fields for ovarian aarcinoma: a modeling study. Adv Radiat Oncol 2021; 6: 100716. doi: 10.1016/j.adro.2021.100716 LokE SanP WhiteV LiangO WidickPC ReddySP Tumor treating fields for ovarian aarcinoma: a modeling study Adv Radiat Oncol 2021 6 100716 10.1016/j.adro.2021.100716 Open DOISearch in Google Scholar

48. Grosso F, Pless M, Ceresoli GL. Safety of tumour treating fields delivery to the torso: meta analysis from TTFields clinical trials. Ann Onco 2019; 30: v187–v8. doi: 10.1093/annonc/mdz244.059 GrossoF PlessM CeresoliGL Safety of tumour treating fields delivery to the torso: meta analysis from TTFields clinical trials Ann Onco 2019 30 v187 v8 10.1093/annonc/mdz244.059 Open DOISearch in Google Scholar

49. Kirson ED, Giladi M, Bomzon Z, Weinberg U, Farber O. INNOVATE-3: phase 3 randomized, international study of tumor treating fields (200 kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer. J Clin Oncol 2018; 36: TPS5614–TPS5614. doi: 10.1200/JCO.2018.36.15_suppl.TPS5614 KirsonED GiladiM BomzonZ WeinbergU FarberO INNOVATE-3: phase 3 randomized, international study of tumor treating fields (200 kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer J Clin Oncol 2018 36 TPS5614 TPS5614 10.1200/JCO.2018.36.15_suppl.TPS5614 Open DOISearch in Google Scholar

50. Sessa C, et al; NovoCure Ltd. An open label pilot study of the novoTTF-100L(O) system (NovoTTF Therapy) (200 kHz) concomitant with weekly paclitaxel for recurrent ovarian carcinoma. ClinicalTrials.gov. Identifier (NCT number): NCT02244502. Available at: https://clinicaltrials.gov/ct2/show/NCT02244502?term=TTFields&cond=ovarian+cancer&draw=2&rank=2 SessaC NovoCure Ltd. An open label pilot study of the novoTTF-100L(O) system (NovoTTF Therapy) (200 kHz) concomitant with weekly paclitaxel for recurrent ovarian carcinoma ClinicalTrials.gov. Identifier (NCT number): NCT02244502 Available at: https://clinicaltrials.gov/ct2/show/NCT02244502?term=TTFields&cond=ovarian+cancer&draw=2&rank=2 Search in Google Scholar

51. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014; 15: 799–808. doi: 10.1016/S1470-2045(14)70244-X MonkBJ PovedaA VergoteI RaspagliesiF FujiwaraK BaeDS Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial Lancet Oncol 2014 15 799 808 10.1016/S1470-2045(14)70244-X Open DOISearch in Google Scholar

52. Vergote I, et al; NovoCure Ltd. Effect of tumor treating fields (TTFields, 200 kHz) concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer (ENGOT-ov50/GOG-3029/INNOVATE-3). ClinicalTrials.gov. Identifier (NCT number): NCT03940196. Available at: https://clinicaltrials.gov/ct2/history/NCT03940196?V_82=View#StudyPageTop VergoteI NovoCure Ltd. Effect of tumor treating fields (TTFields, 200 kHz) concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer (ENGOT-ov50/GOG-3029/INNOVATE-3) ClinicalTrials.gov. Identifier (NCT number): NCT03940196 Available at: https://clinicaltrials.gov/ct2/history/NCT03940196?V_82=View#StudyPageTop Search in Google Scholar

53. Vergote IB, Copeland L, Monk BJ, Coleman RL, Cibula D, Sehouli J, et al. Tumour treating fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: phase III INNOVATE-3/ENGOT-ov50 study. [abstract]. ESMO, Oct 2019. Ann of Oncol 2019; 30(Suppl 5): v431. doi: 10.1093/annonc/mdz250.067 VergoteIB CopelandL MonkBJ ColemanRL CibulaD SehouliJ Tumour treating fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: phase III INNOVATE-3/ENGOT-ov50 study. [abstract]. ESMO, Oct 2019 Ann of Oncol 2019 30 Suppl 5 v431 10.1093/annonc/mdz250.067 Open DOISearch in Google Scholar

54. Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol 2015; 12: 319–34. doi: 10.1038/nrclinonc.2015.53 Garrido-LagunaI HidalgoM Pancreatic cancer: from state-of-the-art treatments to promising novel therapies Nat Rev Clin Oncol 2015 12 319 34 10.1038/nrclinonc.2015.53 Open DOISearch in Google Scholar

55. Carbonero RG, Guillen C, Benavides-Orgaz M, Gallego-Plazas J, Rivera F; NovoCure Ltd. A phase II study of TTFields (150 kHz) concomitant with gemcitabine and TTFields concomitant with gemcitabine plus nab-paclitaxel for front-line therapy of advanced pancreatic adenocarcinoma. ClinicalTrials.gov. Identifier (NCT number): NCT01971281. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT01971281 CarboneroRG GuillenC Benavides-OrgazM Gallego-PlazasJ RiveraF NovoCure Ltd. A phase II study of TTFields (150 kHz) concomitant with gemcitabine and TTFields concomitant with gemcitabine plus nab-paclitaxel for front-line therapy of advanced pancreatic adenocarcinoma ClinicalTrials.gov. Identifier (NCT number): NCT01971281 Available at: https://classic.clinicaltrials.gov/ct2/show/NCT01971281 Search in Google Scholar

56. NovoCure Ltd. Pivotal, randomized, open-label study of tumor treating fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma. ClinicalTrials.gov. Identifier (NCT number): NCT03377491. Available at: https://clinicaltrials.gov/ct2/show/NCT03377491?term=TTFields&cond=Pancreatic+Adenocarcinoma&draw=2&rank=2 NovoCure Ltd. Pivotal, randomized, open-label study of tumor treating fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma ClinicalTrials.gov. Identifier (NCT number): NCT03377491 Available at: https://clinicaltrials.gov/ct2/show/NCT03377491?term=TTFields&cond=Pancreatic+Adenocarcinoma&draw=2&rank=2 Search in Google Scholar

57. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424. doi: 10.3322/caac.21492 BrayF FerlayJ SoerjomataramI SiegelRL TorreLA JemalA Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2018 68 394 424 10.3322/caac.21492 Open DOISearch in Google Scholar

58. Davidi S, Jacobovitch S, Shteingauz A, Martinez-Conde A, Braten O, Tempel-Brami C, et al. Tumor treating Fields (TTFields) concomitant with sorafenib inhibit hepatocellular carcinoma in iitro and in vivo. Cancers 2022; 14: 2959. doi: 10.3390/cancers14122959 DavidiS JacobovitchS ShteingauzA Martinez-CondeA BratenO Tempel-BramiC Tumor treating Fields (TTFields) concomitant with sorafenib inhibit hepatocellular carcinoma in iitro and in vivo Cancers 2022 14 2959 10.3390/cancers14122959 Open DOISearch in Google Scholar

59. NovoCure Ltd. HEPANOVA: A Phase II Trial of tumor treating fields (TTFields, 150khz) concomitant with sorafenib for advanced hepatocellular carcinoma (HCC). ClinicalTrials.gov. Identifier (NCT number): NCT03606590. Available at: https://clinicaltrials.gov/ct2/show/NCT03606590 NovoCure Ltd. HEPANOVA: A Phase II Trial of tumor treating fields (TTFields, 150khz) concomitant with sorafenib for advanced hepatocellular carcinoma (HCC) ClinicalTrials.gov. Identifier (NCT number): NCT03606590 Available at: https://clinicaltrials.gov/ct2/show/NCT03606590 Search in Google Scholar

60. Gkikka E, Touchefeu Y, Mercade TM, Gracián AC, Brunner T, Schultheiß M, et al. HEPANOVA: final efficacy and safety results from a phase 2 study of tumor treating fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma (HCC). [abstract]. IHPBA 15th World Congress. New York, USA, 30 March - 2 April 2022. HPB 2022; 24(Suppl 1): S262–S3. doi: 10.1016/j.hpb.2022.05.551 GkikkaE TouchefeuY MercadeTM GraciánAC BrunnerT SchultheißM HEPANOVA: final efficacy and safety results from a phase 2 study of tumor treating fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma (HCC). [abstract]. IHPBA 15th World Congress. New York, USA, 30 March - 2 April 2022 HPB 2022 24 Suppl 1 S262 S3 10.1016/j.hpb.2022.05.551 Open DOISearch in Google Scholar

61. Jones TH, Song JW, Abushahin L. Tumor treating fields: an emerging treatment modality for thoracic and abdominal cavity cancers. Transl Oncol 2022; 15: 101296. doi: 10.1016/j.tranon.2021.101296 JonesTH SongJW AbushahinL Tumor treating fields: an emerging treatment modality for thoracic and abdominal cavity cancers Transl Oncol 2022 15 101296 10.1016/j.tranon.2021.101296 Open DOISearch in Google Scholar

62. Tsimberidou AM et al; MD Anderson Cancer Center. Phase I Study of tumor treating fields (TTF) in combination with cabozantinib, or with atezolizumab and Nab-paclitaxel in patients with advanced solid tumors involving the abdomen or thorax. ClinicalTrials.gov. Identifier (NCT number): NCT05092373. Available at: https://clinicaltrials.gov/ct2/show/NCT05092373?term=TTFields&cond=Breast+Cancer&draw=2&rank=1 TsimberidouAM MD Anderson Cancer Center Phase I Study of tumor treating fields (TTF) in combination with cabozantinib, or with atezolizumab and Nab-paclitaxel in patients with advanced solid tumors involving the abdomen or thorax ClinicalTrials.gov. Identifier (NCT number): NCT05092373 Available at: https://clinicaltrials.gov/ct2/show/NCT05092373?term=TTFields&cond=Breast+Cancer&draw=2&rank=1 Search in Google Scholar

63. Tuszynski J, Luchko T, Carpenter E, Crawford E. Results of molecular dynamics computations of the structural and electrostatic properties of tubulin and their consequences for microtubules. J Comput Theor Nanosci 2004; 1: 392–7. doi: 10.1166/jctn.2004.042 TuszynskiJ LuchkoT CarpenterE CrawfordE Results of molecular dynamics computations of the structural and electrostatic properties of tubulin and their consequences for microtubules J Comput Theor Nanosci 2004 1 392 7 10.1166/jctn.2004.042 Open DOISearch in Google Scholar

64. Mershin A, Kolomenski AA, Schuessler HA, Nanopoulos DV. Tubulin dipole moment, dielectric constant and quantum behavior: computer simulations, experimental results and suggestions. Biosystems 2004; 77: 73–85. doi: 10.1016/j.biosystems.2004.04.003 MershinA KolomenskiAA SchuesslerHA NanopoulosDV Tubulin dipole moment, dielectric constant and quantum behavior: computer simulations, experimental results and suggestions Biosystems 2004 77 73 85 10.1016/j.biosystems.2004.04.003 Open DOISearch in Google Scholar

65. Mungan CE, Lasinski A. Motion of an electric dipole in a static electromagnetic field. Lat Am J Phys Educ 2008; 2: 192–4. MunganCE LasinskiA Motion of an electric dipole in a static electromagnetic field Lat Am J Phys Educ 2008 2 192 4 Search in Google Scholar

66. Riley MM, San P, Lok E, Swanson KD, Wong ET. The clinical application of tumor treating fields Therapy in Glioblastoma. J Vis Exp 2019; 146: e58937. doi: 10.3791/58937 RileyMM SanP LokE SwansonKD WongET The clinical application of tumor treating fields Therapy in Glioblastoma J Vis Exp 2019 146 e58937 10.3791/58937 Open DOISearch in Google Scholar

67. Silginer M, Weller M, Stupp R, Roth P. Biological activity of tumor-treating fields in preclinical glioma models. Cell Death Dis 2017; 8: e2753. doi: 10.1038/cddis.2017.171 SilginerM WellerM StuppR RothP Biological activity of tumor-treating fields in preclinical glioma models Cell Death Dis 2017 8 e2753 10.1038/cddis.2017.171 Open DOISearch in Google Scholar

68. Zhao Y, Zhang G. Elucidating the mechanism of 200 kHz tumor treating fields with a modified DEP theory. 2018 IEEE International Symposium on Signal Processing and Information Technology (ISSPIT). 6–8 Dec 2018, Luisville, USA. pp 1–5. doi: 10.1109/ISSPIT.2018.8705145 ZhaoY ZhangG Elucidating the mechanism of 200 kHz tumor treating fields with a modified DEP theory 2018 IEEE International Symposium on Signal Processing and Information Technology (ISSPIT) 6–8 Dec 2018 Luisville, USA 1 5 10.1109/ISSPIT.2018.8705145 Open DOISearch in Google Scholar

69. Wick W. TTFields: where does all the skepticism come from? Neuro-Oncol 2016; 18: 303–5. doi: 10.1093/neuonc/now012 WickW TTFields: where does all the skepticism come from? Neuro-Oncol 2016 18 303 5 10.1093/neuonc/now012 Open DOISearch in Google Scholar

70. Gagliardi LJ. Electrostatic force in prometaphase, metaphase, and anaphase-A chromosome motions. Physi Rev E 2002; 66: 011901. doi: 10.1103/PhysRevE.66.011901 GagliardiLJ Electrostatic force in prometaphase, metaphase, and anaphase-A chromosome motions Physi Rev E 2002 66 011901 10.1103/PhysRevE.66.011901 Open DOISearch in Google Scholar

71. Gagliardi LJ. Electrostatic force generation in chromosome motions during mitosis. J Electrost 2005; 63: 309–327. doi: 10.1016/j.elstat.2004.09.007 GagliardiLJ Electrostatic force generation in chromosome motions during mitosis J Electrost 2005 63 309 327 10.1016/j.elstat.2004.09.007 Open DOISearch in Google Scholar

72. Gagliardi LJ. Microscale electrostatics in mitosis. J Electrost 2002; 54: 219–32. doi: 10.1016/S0304-3886(01)00155-3 GagliardiLJ Microscale electrostatics in mitosis J Electrost 2002 54 219 32 10.1016/S0304-3886(01)00155-3 Open DOISearch in Google Scholar

73. Stracke R, Böhm KJ, Wollweber L, Tuszynski JA, Unger E. Analysis of the migration behaviour of single microtubules in electric fields. Biochem Biophys Res Commun 2002; 293: 602–9. doi: 10.1016/S0006-291X(02)00251-6 StrackeR BöhmKJ WollweberL TuszynskiJA UngerE Analysis of the migration behaviour of single microtubules in electric fields Biochem Biophys Res Commun 2002 293 602 9 10.1016/S0006-291X(02)00251-6 Open DOISearch in Google Scholar

74. Zhang Y, Chen X. Blood cells separation microfluidic chip based on dielectrophoretic force. J Braz Soc Mech Sci Eng 2020; 42: 1–11. doi: 10.1007/s40430-020-02284-8 ZhangY ChenX Blood cells separation microfluidic chip based on dielectrophoretic force J Braz Soc Mech Sci Eng 2020 42 1 11 10.1007/s40430-020-02284-8 Open DOISearch in Google Scholar

75. Carrieri FA, Smack C, Siddiqui I, Kleinberg LR, Tran PT, et al. Tumor treating fields: at the crossroads between physics and biology for cancer treatment. Front Oncol 2020; 10: 575992. doi: 10.3389/fonc.2020.575992 CarrieriFA SmackC SiddiquiI KleinbergLR TranPT Tumor treating fields: at the crossroads between physics and biology for cancer treatment Front Oncol 2020 10 575992 10.3389/fonc.2020.575992 Open DOISearch in Google Scholar

76. Alexander S, Rieder CL. Chromosome motion during attachment to the vertebrate spindle: initial saltatory-like behavior of chromosomes and quantitative analysis of force production by nascent kinetochore fibers. J Cell Biol 1991; 113: 805–15. doi: 10.1083/jcb.113.4.805 AlexanderS RiederCL Chromosome motion during attachment to the vertebrate spindle: initial saltatory-like behavior of chromosomes and quantitative analysis of force production by nascent kinetochore fibers J Cell Biol 1991 113 805 15 10.1083/jcb.113.4.805 Open DOISearch in Google Scholar

77. Li X, Yang F, Gao B, Yu X, Rubinsky B. A theoretical analysis of the effects of tumor-treating electric fields on single cells. Bioelectromagnetics 2020; 41: 438–46. doi: 10.1002/bem.22274 LiX YangF GaoB YuX RubinskyB A theoretical analysis of the effects of tumor-treating electric fields on single cells Bioelectromagnetics 2020 41 438 46 10.1002/bem.22274 Open DOISearch in Google Scholar

78. Berkelmann L, Bader A, Meshksar S, Dierks A, Hatipoglu Majernik G, Krauss JK, et al. Tumour-treating fields (TTFields): investigations on the mechanism of action by electromagnetic exposure of cells in telophase/cytokinesis. Sci Rep 2019; 9: 7362. doi: 10.1038/s41598-019-43621-9 BerkelmannL BaderA MeshksarS DierksA Hatipoglu MajernikG KraussJK Tumour-treating fields (TTFields): investigations on the mechanism of action by electromagnetic exposure of cells in telophase/cytokinesis Sci Rep 2019 9 7362 10.1038/s41598-019-43621-9 Open DOISearch in Google Scholar

79. Geng T, Lu C. Microfluidic electroporation for cellular analysis and delivery. Lab Chip 2013; 13: 3803–21. doi: 10.1039/C3LC50566A GengT LuC Microfluidic electroporation for cellular analysis and delivery Lab Chip 2013 13 3803 21 10.1039/C3LC50566A Open DOISearch in Google Scholar

80. Chang E, Patel CB, Pohling C, Young C, Song J, Flores TA, et al. Tumor treating fields increases membrane permeability in glioblastoma cells. Cell Death Discov 2018; 4: 113. doi: 10.1038/s41420-018-0130-x ChangE PatelCB PohlingC YoungC SongJ FloresTA Tumor treating fields increases membrane permeability in glioblastoma cells Cell Death Discov 2018 4 113 10.1038/s41420-018-0130-x Open DOISearch in Google Scholar

81. Kurtz-Nelson EC, Rea HM, Petriceks AC, Hudac CM, Wang T, Earl RK, et al. Alternating electric fields (TTFields) activate Cav1. 2 channels in human glioblastoma cells. Cancers 2019; 11: 110. doi: 10.3390/cancers11010110 Kurtz-NelsonEC ReaHM PetriceksAC HudacCM WangT EarlRK Alternating electric fields (TTFields) activate Cav1. 2 channels in human glioblastoma cells Cancers 2019 11 110 10.3390/cancers11010110 Open DOISearch in Google Scholar

82. Gal V, Martin S, Bayley P. Fast disassembly of microtubules induced by Mg²⁺ or Ca²⁺. Biochem Biophys Res Commun 1988; 155: 1464–1470. doi: 10.1016/S0006-291X(88)81306-8 GalV MartinS BayleyP Fast disassembly of microtubules induced by Mg²⁺ or Ca²⁺ Biochem Biophys Res Commun 1988 155 1464 1470 10.1016/S0006-291X(88)81306-8 Open DOISearch in Google Scholar

83. Voloshin T, Kaynan N, Davidi S, Porat Y, Shteingauz A, Schneiderman RSet al. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Cancer Immunol Immunother 2020; 69: 1191–204. doi: 10.1007/s00262-020-02534-7 VoloshinT KaynanN DavidiS PoratY ShteingauzA SchneidermanRS Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy Cancer Immunol Immunother 2020 69 1191 204 10.1007/s00262-020-02534-7 Open DOISearch in Google Scholar

84. Tanzhu G, Chen L, Xiao G, Shi W, Peng H, Chen D, et al. The schemes, mechanisms and molecular pathway changes of tumor treating fields (TTFields) alone or in combination with radiotherapy and chemotherapy. Cell Death Discov 2022; 8: 416. doi: 10.1038/s41420-022-01206-y TanzhuG ChenL XiaoG ShiW PengH ChenD The schemes, mechanisms and molecular pathway changes of tumor treating fields (TTFields) alone or in combination with radiotherapy and chemotherapy Cell Death Discov 2022 8 416 10.1038/s41420-022-01206-y Open DOISearch in Google Scholar

85. Chen D, Le SB, Hutchinson TE, Calinescu AA, Sebastian M, Jin D, et al. Tumor treating fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma. J Clin Invest 2022; 132: e149258. doi: 10.1172/JCI149258 ChenD LeSB HutchinsonTE CalinescuAA SebastianM JinD Tumor treating fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma J Clin Invest 2022 132 e149258 10.1172/JCI149258 Open DOISearch in Google Scholar

86. Shteingauz A, Porat Y, Voloshin T, Schneiderman RS, Munster M, Zeevi E, et al. AMPK-dependent autophagy upregulation serves as a survival mechanism in response to tumor treating fields (TTFields). Cell Death Dis 2018; 9: 1074. doi: 10.1038/s41419-018-1085-9 ShteingauzA PoratY VoloshinT SchneidermanRS MunsterM ZeeviE AMPK-dependent autophagy upregulation serves as a survival mechanism in response to tumor treating fields (TTFields) Cell Death Dis 2018 9 1074 10.1038/s41419-018-1085-9 Open DOISearch in Google Scholar

87. Kim EH, Jo Y, Sai S, Park MJ, Kim JY, Kim JS, et al. Tumor-treating fields induce autophagy by blocking the Akt2/miR29b axis in glioblastoma cells. Oncogene 2019; 38: 6630–46. doi: 10.1038/s41388-019-0882-7 KimEH JoY SaiS ParkMJ KimJY KimJS Tumor-treating fields induce autophagy by blocking the Akt2/miR29b axis in glioblastoma cells Oncogene 2019 38 6630 46 10.1038/s41388-019-0882-7 Open DOISearch in Google Scholar

88. Lee YJ, Cho JM, Sai S, Oh JY, Park JA, Oh SJ, et al. 5-Fluorouracil as a tumor-treating field-sensitizer in colon cancer therapy. Cancers 2019; 11: 1999. doi: 10.3390/cancers11121999 LeeYJ ChoJM SaiS OhJY ParkJA OhSJ 5-Fluorouracil as a tumor-treating field-sensitizer in colon cancer therapy Cancers 2019 11 1999 10.3390/cancers11121999 Open DOISearch in Google Scholar

89. Shiratori R, Furuichi K, Yamaguchi M, Miyazaki N, Aoki H, Chibana H, et al. Glycolytic suppression dramatically changes the intracellular metabolic profile of multiple cancer cell lines in a mitochondrial metabolism-dependent manner. Sci Rep 2019; 9: 18699. doi: 10.1038/s41598-019-55296-3 ShiratoriR FuruichiK YamaguchiM MiyazakiN AokiH ChibanaH Glycolytic suppression dramatically changes the intracellular metabolic profile of multiple cancer cell lines in a mitochondrial metabolism-dependent manner Sci Rep 2019 9 18699 10.1038/s41598-019-55296-3 Open DOISearch in Google Scholar